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Abstract
Background: Secretion of human chorionic gonadotropin, especially its beta subunit by malignant
trophoblastic tumors and varieties of tumors of different origin is now well documented; however
the role of hCG in tumorogenesis is still unknown.
Results: This study documents the molecular presence of human chorionic gonadotropin beta
subunit in uterine cervix cancer tissues and investigates a novel technique to reduce hCGβ levels
based on expression of a modified U1 snRNA as a method to study the hormone's role in biology
of human cervical cancer cells cultured in vitro. The property of U1 snRNA to block the
accumulation of specific RNA transcript when it binds to its donor sequence within the 3' terminal
exon was used. The first 10 nucleotides of the human U1 snRNA gene, which normally binds to
the 5'ss in pre-mRNA were replaced by a sequence complementary to a 10-nt segment in the
terminal exon of the hCGβ mRNA. Three different 5' end-mutated U1 snRNA expression plasmids
were tested, each targeting a different sequence in the hCGβ mRNA, and we found each one
blocked the expression of hCGβ  in HeLa cells, a cervix carcinoma cell line, as shown by
immunohistochemistry and qRT-PCR. Reduction of hCGβ levels resulted in a significantly increased
apoptosis rate with almost 90% of cells transfected with modified anti-hCGβ U1 snRNAs showing
morphological changes characteristic of the apoptotic process.
Conclusion: These data suggest that human chorionic gonadotropin beta subunit may act as a
tumor growth-stimulating factor.
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Background
Human chorionic gonadotropin is a heterodimeric glyco-
protein that belongs to the family of related hormones
included FSH, LH and TSH. The hormone is composed of
two non-covalently linked subunits, the common alfa
subunit (hCGα) and the hormone specific beta subunit
(hCGβ) [1]. Human chorionic gonadotropin (hCG) is a
hormone physiologically produced by the placenta to
maintain the progesterone production of corpus luteum
of pregnancy, which prepares the uterus for implantation
and for embryonic and placental development [2].
The ectopic production of hCG and its subunits by
patients with nontrophoblastic cancers has been reported
by many authors lately [3]. The free subunit was originally
considered as biologically non-functional, however it was
shown recently that free β-subunit may stimulate tumor
growth or inhibit its apoptosis and the elevated serum
level of hCGβ is frequently associated with higher aggres-
siveness of cancer and its resistance to therapy [4,5].
We recently reported the expression of hCGβ in patients
with nontrophoblastic gynecological cancerous tissues
showing that the beta subunit of human chorionic gona-
dotropin is produced by individual cancer cells. The dis-
tribution and the amount of hCG was heterogeneous and
was not characteristic for all of the cells of the study tissue
[6,7].
Here we confirm that the presence of the beta subunit of
human chorionic gonadotropin's mRNA and protein is a
characteristic feature of cervical carcinomas. The biologi-
cal mechanisms behind the association of hCGβ expres-
sion in cancer cells remains unclear. Silencing gene
expression provides a powerful tool for analyzing gene
function, however the effectiveness of RNA inhibition
strategies has been variable. Based on this we investigated
a novel mRNA silencing methodology as a method to
study hCGβ role in human cervical cancer cells cultured in
vitro. Since nearly all mRNAs are postranscriptionally
modified by 5'capping, splicing, 3' cleavage and polyade-
nylation it was postulated that agents interfering with
processing of specific transcripts have the potential to be
an effective anti-RNA strategy. Recently an approach for
reducing mRNA output of a target gene was reported that
is based on a modified U1 snRNA transcript as an effector.
The interaction of U1 snRNP (small nuclear ribonucleo-
protein particle) via base paring close to the polyadenyla-
tion signal results in inhibition of the cleavage or
polyadenylation portion of the 3' end processing reaction
[8,9]. This effect was applied to suppress other genes. A
significant inhibition of gene expression was achieved by
using a modified U1 snRNA in which the first 10 nucle-
otides have been substituted with a sequence complemen-
tary to the gene of interest present within the terminal
exon [10-12].
In our study we exploit 5' end-mutated U1 snRNAs to
block the expression of hCGβ in a cervix carcinoma cell
line. The results have been demonstrated that U1 snRNA
base paired to this target mRNA inhibits the expression of
the beta subunit of human gonadotropin gene causing
apoptotic death of affected cells.
Results
Expression of hCGβ is a characteristic feature of cervix 
carcinoma cancer
To verify at the molecular level the presence of hCGβ in
uterine cervix carcinoma, total RNA was isolated from
cancer tissue of patients, reverse transcribed, and a 210 bp
fragment corresponding to hCGβ  nucleotides 348–557
[GenBank: NM_033043] was amplified. In total, 15 sam-
ples of human uterine cervix carcinoma and 4 samples of
placenta were analyzed. A representative example of the
RT-PCR data is shown in Figure 1A where it is evident that
we were able to amplify a specific fragment of hCGβ.
Sequencing of the amplified fragment confirmed its iden-
tity with hCGβ.
There was, however, no amplification of hCGβ fragment
when cDNA synthesized from RNA isolated from tissue
lacking cancerous changes (myometrium and uterine cer-
vix) was used as a template for the PCR reaction (Figure
1B. lanes 1, 3, 5). The presence of the 509 bp fragment
corresponding to β-actin gene nucleotides 434–942 [Gen-
Bank:X00351] in the tissues lacking hCGβ served as a con-
trol and confirmed the integrity of isolated RNA (Figure
1B. lanes 2, 4, 6).
We conclude that the expression of hCGβ is a property of
uterine cervix tumor cells.
Human chorionic gonadotropin is synthesised by cancer 
cells of the uterine cervix
To verify the presence of hCG on the protein level and to
address localisation of the hormone in cancer tissue,
immunohistochemical analyses were carried out with pri-
mary antibodies against hCG. Hormone staining was
localized predominantly in the neoplastically trans-
formed tumor epithelial cells, characterised by uniform
and homogenous cytoplasmic staining, however a single
positive cells in stroma were detected (Figure 2).
No labeling was observed in the control reactions – where
the primary antibodies were omitted (data not shown).
Inhibition of hCGβ in HeLa cell line using modified U1
To block the expression of hCGβ in tumor cells the mRNA
was targeted with three plasmids that encode U1 snRNAMolecular Cancer 2008, 7:26 http://www.molecular-cancer.com/content/7/1/26
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with 5'end-mutated U1 snRNA transgenes designed to rec-
ognize a 10 nucleotide-long sequences in the 3' terminal
exon of hCGβ pre-mRNA (Figure 3).
Because inhibition levels are limited by transfection effi-
ciency – for example a 90% transfection rate can at most
give a 10-fold inhibition [11], and in case of using HeLa
cell line and lipofectamine™2000 transfection reagent the
efficiency estimated by GFP reporter gene expression was
lower than 30% we applied quantitative RT-PCR to show
the silencing of human chorionic gonadotropin beta sub-
unit expression. hCGβ transcripts were detected in both
control and transfected cells however, all 3 U1 snRNA
anti-hCGβ constructs clearly reduced the hormone's tran-
scription as was showed by real time PCR results. The
highest – 3-fold inhibition was observed for 702P/767A
plasmid. Constructs 702P/767B and 702P/767C
decreased hCGβ mRNA amount 2-times while the expres-
sion level of cells transfected with 702P plasmid and con-
trol cells was the same (Figure 4). Using FuGENE – HD
Transfection Reagent we got 60% transfection efficiency
and the level of hormone inhibition was the same as
when transfection efficiency was 30% (data not shown).
The immunohistochemistry data confirmed the blocking
of human chorionic gonadotropin synthesis. HeLa cells
transfected with U1 snRNA anti-hCGβ constructs, and cul-
tured for 72 hours were fixed and immunostained for
hCG. We found that all three anti-hCGβ constructs, but
not the 702P control plasmid, attenuated the human cho-
rionic gonadotropin expression to levels below detection
(Figure 5A).
Expression of human chorionic beta subunit in uterine cervix Figure 1
Expression of human chorionic beta subunit in uter-
ine cervix. (A) Electrophoretic separation showing repre-
sentative RT-PCR results performed for uterine cervix 
carcinomas. A 210 bp fragment of hCGβ was amplified for the 
uterine cervix carcinoma (lanes 1 – 4) and placenta (lane 5) 
samples. Molecular size marker is given in lane M. (B) RT-
PCR analysis of total RNA from normal myometrium (lanes 
1–2) and uterine cervix tissue (lanes 3–6). Lanes 1, 3 and 5 
used RT-PCR primers specific to the hCGβ mRNA as was 
done in Figure 1A. Lanes 2, 4 and 6 are control RT-PCRs 
with primers specific to the β-actin mRNA (predict a 509 bp 
product) to confirm the integrity of the RNA. M – size 
marker.
Immunolocalisation of hCG in cervical carcinoma Figure 2
Immunolocalisation of hCG in cervical carcinoma. 
Immunohistochemistry was performed using specific antibod-
ies against hCG on paraffin section of tumor tissue. Hor-
mone staining was localized predominantly in the 
neoplastically transformed epithelial cells as indicated by the 
arrows. Positive immunostaining was also detected in single 
cells in stroma – arrowheads. Original magnification, ×400.
Schematic of the 3 anti-hCGβ U1 snRNA targeting vectors  containing a U1 snRNA gene to drive expression of the anti- hCGβ U1 snRNAs Figure 3
Schematic of the 3 anti-hCGβ U1 snRNA targeting vectors 
containing a U1 snRNA gene to drive expression of the anti-
hCGβ U1 snRNAs. Schematic showing predicted base pairing 
interaction of each anti-hCGβ U1 snRNA with the hCGβ 
mRNA.Molecular Cancer 2008, 7:26 http://www.molecular-cancer.com/content/7/1/26
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Silencing of hCGβ results in apoptosis of cancer cells
Next we determined whether the expression of 5'end-
mutated U1 snRNA transgenes causing the inhibition of
hCGβ gene can affect the viability of cells. To assess the
effect of transfection of anti-hCGβ constructs on cancer
cells the morphological features after staining with pro-
pidium iodide and Hoechst 33342 were observed. The
cells transfected with a modified U1 snRNA showed
changes typical for apoptosis. The nuclei condensation
and fragmentation was detected particularly in approxi-
mately 90% cells expressing U1 snRNA anti-hCGβ con-
struct as well as in some neighbouring cells lacking the
modified U1 snRNA (Figure 5B,C). The number of these
latter cells does not exceed 20%. The cells transfected with
the 702P control construct did not show any significant
changes and only a few apoptotic cells were observed
(data not shown).
Changes in cell cycles distribution were monitored by
flow cytometry. The inhibition of hCGβ  expression by
anti-hCGβ constructs result in increase in distribution of
cells at sub-G1 peak – apoptosis peak (Figure 6). The per-
centage of apoptotic cells was increased to 26.65%,
23.59% and 22.48% for 702P/767A, 702P/767B and
702P/767C plasmids respectively (Table 1).
Discussion
Human chorionic gonadotropin (hCG), a heterodimeric
sialoglycoprotein hormone composed of two noncova-
lently linked subunits – α (hCGα) and β (hCGβ) is phys-
iologically produced by the placenta [13]. Numerous
studies demonstrated that besides placenta and malignant
Expression of hCGβ in HeLa cells transfected with anti-hCGβ  U1 snRNA Figure 4
Expression of hCGβ in HeLa cells transfected with 
anti-hCGβ U1 snRNA. Total RNA was isolated from cells, 
and cDNA was synthesized. HeLa cells transfected with plas-
mids 702P/767A, 702P/767B and 702P/767C expressed 
decreased hCGβ message relative to control cells and cells 
transfected with control plasmid 702P. Columns – mean of 
triplicate experiments; bars – SE.
Anti-hCGβ constructs knock down human chorionic gonado- tropin protein expression and cause apoptosis Figure 5
Anti-hCGβ constructs knock down human chorionic 
gonadotropin protein expression and cause apopto-
sis. (A) Immunohistochemistry was performed using primary 
antibodies against hCG and secondary antibody conjugated 
with Cy3. The positive staining (orange – FT 510 filter) was 
observed in cells lacking anti-hCGβ construct – arrowheads. 
hCG was not detected in cells transfected with the anti-hCGβ 
U1 snRNA construct 702P/767A that co-expresses GFP 
(green – FT 510 filter) as a marker – arrows. Original magni-
fication ×1000.(B) Blue Hoechst staining of living cells. (C) 
Propidium iodide red staining of dead cells and GFP staining 
of cells transfected with U1 constructs. Chromatin conden-
sation and fragmentation in the nuclei of apoptotic cells 
stained were showed by arrows. Original magnification, 
×400.Molecular Cancer 2008, 7:26 http://www.molecular-cancer.com/content/7/1/26
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trophoblastic disease, varieties of tumors of different ori-
gin secreted hCG and especially its β-subunit [3,14,15]. As
previously demonstrated by Acevedo and Hartsock, in a
nude mouse model, high expression of membrane-associ-
ated hCGβ correlates with primary malignant growth and
metastatic phenotype of cancer [14].
The findings of present study indicate the hCGβ gene is
active in uterine cervix cancers. In all 15 specimens of the
cervical carcinomas that were analyzed, the transcripts of
hCGβ were present. Even in slightly advanced carcinomas
such as carcinoma of uterine cervix, FIGO stage 0, IA we
found the mRNA of hCGβ. At the same time we showed
that tissue lacking the cancerous changes did not express
hCGβ mRNA. The RT-PCR results were proofed by immu-
Effect of transfection with anti-hCGβ U1 snRNA on apoptotic rate in HeLa cells Figure 6
Effect of transfection with anti-hCGβ U1 snRNA on apoptotic rate in HeLa cells. FACS analyses using propidium 
iodide staining was performed for DNA content measurement. Apoptotic population was measured as the percentage of total 
cell population with sub-G1 DNA content. Results shown represents experiments performed for control cells and cells trans-
fected with plasmid 702P and 702P/767A, respectively.
Table 1: Effect of hCGβ silencing on cell cycle of HeLa cells. n = 3. Mean ± SD.
Apoptotic [%] G0/1 [%] S [%] G2/M [%]
Control 1.82 ± 0.09 56.06 ± 2.80 23.38 ± 1.17 8.01 ± 0.40
p702P 3.13 ± 0.16 45.73 ± 2.29 26.43 ± 1.32 11.33 ± 0.57
p702P/767A 26.65 ± 1.33 27.15 ± 1.36 21.36 ± 1.07 8.56 ± 0.43
p702P/767B 23.59 ± 1.18 31.27 ± 1.56 19.24 ± 0.96 15.29 ± 0.76
p702P/767C 22.48 ± 1.12 30.76 ± 1.54 22.27 ± 1.11 12.96 ± 0.65Molecular Cancer 2008, 7:26 http://www.molecular-cancer.com/content/7/1/26
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nohistochemical analysis, which revealed that hCG is
expressed in cancer cells within a cervical carcinoma.
Thus, the expression of hCGβ is a characteristic feature of
cervical tumor tissue, however the role of hCG in tumoro-
genesis is unknown.
The discovery of the crystal structure of hCG demon-
strated that dimeric hCG forms the cystine knot structure
[16]. The structure of hCG resembles the structure of
known growth factors, namely TGFβ (Transforming
Growth Factor), NGF (Nerve Growth Factor) and PDGFβ
(Platelet Derived Growth factor) [16,17]. It was actually
shown that subjection of an hCGβ-secreting bladder
tumor cell line to stimulation by hCGβ in vitro led to an
increase in cell number, in a dose dependent manner [4].
Guided by these observations we reasoned that the reduc-
tion of the hormone level would result in decrease of cell
viability. We used a new strategy to knock down the
expression of hCGβ  in cultured cervix carcinoma cells.
Mammalian U1 snRNP contains ten proteins bound to
U1 snRNA and binds to the exon-intron boundary of pre-
mRNA to direct early steps of splicosome formation [18].
Binding involves the interaction between nucleotides 2–
11 of the human U1 snRNA and the 5' splice site of pre-
mRNA. A modified U1 snRNA can be used as an alterna-
tive to siRNA, antisense RNA or ribozyme approach for
reducing the mRNA output of a target gene. In our study
we examined whether binding of modified U1 snRNAs to
10 nucleotide regions within the terminal exon of human
chorionic gonadotropin beta subunit was able to inhibit
the hormone synthesis.
We demonstrated that U1 complementary to three differ-
ent target regions of hCGβ pre-mRNA results in suppres-
sion of the hormone expression both on the mRNA and
protein level. The fact that three different modified U1
snRNAs gave similar results would argue that hCGβ reduc-
tion, as opposed to off-target effects by each modified U1
snRNA, is responsible for the effects we observe. Our
results indicated that HeLa cells trasfected with U1 snRNA
anti-hCGβ  constructs showed 2–3-fold inhibition of
human chorionic gonadotropin beta subunit transcripts.
In cancer cells expressing the modified U1 snRNAs hCG
protein was undetectable. Further analysis showed that
knocking down gonadotropin expression significantly
increases the apoptosis rate what was shown by flow
cytometry and morphological changes characteristic for
apoptotic process. Thus, the inhibition of the beta subunit
of human chorionic gonadotropin expression leads to
induction of programmed cell death.
It was already shown that the addition of anti-hCGβ anti-
bodies to the culture media of bladder cancer cell line
inhibit the growth of the cells which produce endogenous
free hCGβ [4]. Furthermore Rivera et al., as a result of
applying the antisense RNA specific to hCGβ, demon-
strated the loss of tumorogenic potential of human lung
cancer cells (ChaGo cells), cultured in vitro [19]. Also the
transfection of an antisense chorionic gonadotropin beta
gene into choriocarcinoma cells suppressed cell prolifera-
tion and increased the apoptosis-positive rate of JAr cells
[20].
Recent reports suggest that free hCGβ is acting as a
growth-stimulating factor, but the population growth is
not the result of increased replication rate but of reduction
in cell apoptosis [3,21]. Since the induction of epithelial
cell apoptosis is a well-established action of TGFβ and the
topological homology of hCGβ and TGFβ was previously
shown it was suggested that the anti-apoptotic effect of
hCGβ could potentially occur by blocking the TGFβ recep-
tor. Blocking of the receptor by free hCGβ could prevent
any further interactions with other components that are
necessary for initiating cytoplasmic signaling that leads to
apoptosis [3].
The inhibition of hCGβ  expression by modified U1
snRNAs caused apoptosis both in cells expressing U1 anti-
hCGβ construct as well as in neighbouring cells, lacking
the modified U1 snRNA. This neighboring cell effect
could be explained by a decreased level of hCGβ in culture
medium, which allows the interactions between the
receptor and ligands essential for induction of apoptosis.
Therefore our results are in good agreement with the date
published previously.
Conclusion
The results of the study demonstrated that blocking of
human chorionic gonadotropin beta subunit by modified
U1 complementary to three different target regions of its
pre-mRNA results in suppression of the hormone expres-
sion both on the mRNA and protein level. The knocking
down gonadotropin expression significantly increases the
apoptosis rate of affected cells.
While current anti-hCGβ therapeutic strategies are based
on antibody blockade of ectopically expressed hCGβ here
we demonstrated, in vitro, the potential of mRNA silenc-
ing gene technology to achieve the same therapeutic
results via the same molecular mechanism, increased
endogenous apoptosis.
Materials and methods
The specimens of gynecological cancer tissue were
obtained from patients treated by surgery at the Depart-
ment of Gynecologic Oncology, Poznan University of
Medical Sciences in 2004 – 2006. The uterine cervix carci-
noma group consisted of 15 patients with epithelial carci-
noma of the uterine cervix. In all patients, histologicalMolecular Cancer 2008, 7:26 http://www.molecular-cancer.com/content/7/1/26
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proof, including tumor grading, was obtained and the
staging was performed according to FIGO.
Histology groups were as follows: Carcinoma planoepi-
theliale (12 cases; tumor grading: G1 – n = 6, G2 – n = 6;
FIGO: IA – n = 2, IIA – n = 1, IB – n = 7, IIB – n = 1, IIIAB
– n = 1), Glassy cell carcinoma (1 case; tumor grading –
not determinate; FIGO IB), Basaloid cell carcinoma (1
case; tumor grading – not determinate; FIGO IIB), Carci-
noma intraepitheliale CIN III (1 case; tumor grading – not
determinate; FIGO 0). No patients received chemotherapy
or radiotherapy prior to operation.
The control included two samples of the myometrium
and three samples of the uterine cervix that lacked cancer-
ous changes as estimated by a pathologist's macroscopic
and microscopic examination. Four placentas from term
pregnancies served as a control. The placentas were
obtained from the Department of Perinatology Karol
Marcinkowski University of Medical Sciences, Poznan,
Poland.
Tissue samples were frozen in liquid nitrogen or fixed in
4% paraformaldehyde.
The study was approved by the ethics review board of
Poznan University of Medical Sciences and all patients
participated after informed consent.
HeLa cell line, established from cells of cervix carcinoma
and producing human chorionic gonadotropin served as
an in vitro model of nontrophoblastic gynecological can-
cer. The cells were cultured and passaged under standard
conditions.
RNA isolation and RT-PCR
Total cellular RNA was extracted in TriPure (Roche Diag-
nostic, Mannheim, Germany) according to manufacture
protocols.
1 µg of RNA (DNase treated) was employed individually
for one reverse transcription reaction with universal
primer p(dT)10 and Expand Reverse Transcriptase (Roche
Diagnostic).
A 210 bp fragment of hCGβ was amplified from cDNA
using the following primers: sense 5'-GCAGGGGACG-
CACCAAGGA-3' (nucleotides 348–367, according to
cDNA sequence) and antisense 5'-CACGCGGGTCAT-
GGTGGG-3' (complementary to nucleotides 539–557,
[GenBank:NM_033043]). The amplification was per-
formed in a reaction mixture containing: 1× Taq DNA
polymerase buffer, 2.5 mM MgCl2, 0.2 mM dNTPs, 0.25
µM of each primer and 1 unit of BioX-Act DNA polymer-
ase (Bioline, London, UK) with thermal profile as fol-
lowed: 5 min at 95°C, 1 min at 95°C, 45 sec at 64°C, 45
sec at 72°C for 30 cycles. The quality of RNA was checked
by examining ribosomal RNA bands after agarose gel elec-
trophoresis and by amplifying β-actin  as a control. All
products were sequenced to confirm their identity.
Quantitative RT-PCR
To quantify the amount of hCGβ and GAPDH (internal
control) in HeLa cells after RNA isolation, reverse tran-
scription real-time PCR with LightCycler 2.0 (Roche Diag-
nostics) and LightCycler FastStart DNA Master SYBR
Green I Kit (Roche Diagnostics) was performed. 20 µl of
PCR reaction mixture contain: 2.5 mM of MgCl2, 2 µl of
SYBR Green 1 mix, 2 µl of cDNA and a 0.5 µM of each
primer. hCGβ primers sequence was as described above
and GAPDH primers were designed as follow: sense – 5'-
CAG CCT CAA GAT CAT CAG C-3' and antisense – 5'-
GAC TGT GGT CAT GAG TCC TCC-3' [Gen-
Bank:NM_002046]. The amplification program consisted
of 1 cycle of 95°C with a 10 min hold, followed by 45
cycles of 95°C with a 10 s hold, annealing temperature at
62°C (hCGβ) or 58°C (GAPDH) with a 5 s hold, and
72°C with a 9 s hold. An additional step was added for
fluorescence data acquisition at an elevated temperature
for hCGβ amplification, which is 88°C with a 2 s hold.
This was followed by melting curve analysis, which ran for
1 cycle at 95°C with a 0 s hold, 65°C with a 15 s hold, and
95°C with a 0 s hold at the step acquisition mode.
All experiments were performed in triplicates. PCR effi-
ciencies were calculated from the standard curves (gener-
ated using serial dilutions of in vitro generated transcripts)
for hCGβ and GAPDH. Melting curve analysis (LighCycler
software package) was applied to ensure the specificity of
the PCR reaction. A relative expression level of hCGβ gene
was normalized with GAPDH.
Immunohistohchemistry
Paraffin sections of analysed tissue fixed in 4% parafor-
maldehyde were used for immunohistochemical detec-
tion of hCG. Antigens were retrieved by microwave
activation in citrate buffer (10 mM, pH 6.0). After being
blocked in blocking buffer – TBS, pH 7.5, containing (100
mM TRIS-HCl, 0.9% NaCl, 0.05% Tween-20 (TBS-T) and
1% BSA) sections were incubated with primary rabbit pol-
yclonal antibodies against hCG (DAKO A/S, Glostrup,
Denmark) diluted 1:200 in blocking buffer for 60 minutes
at 37°C in a humidified chamber and washed 4 × 15 min-
utes in TBS-T. AP-conjugated anti-rabbit IgG, diluted
1:200 (Sigma-Aldrich, Saint Louis, Mi, USA) and NBT/
BCIP (Sigma) as the substrate were used for detection.
Incubation and washing conditions were as described for
primary antibodies. Controls included detection reactions
carried out under identical conditions except that the pri-
mary antibodies were replaced by nonimmune serum.Molecular Cancer 2008, 7:26 http://www.molecular-cancer.com/content/7/1/26
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At 72 hours after transfection HeLa cells were rinsed in
PBS, fixed in 4% paraformaldehyde for 5 minutes at room
temperature and blocked in blocking buffer. Then they
were incubated with primary rabbit polyclonal antibodies
against hCG diluted 1:200 in blocking buffer for 60 min-
utes at 37°C. For the detection of antigen-primary anti-
body complex the secondary Cy3-conjugated antibodies
(Sigma) diluted 1:200 were used. The reaction was visual-
ized with fluorescence microscope (Zeiss, Axioskop 2)
with appropriate filters for GFP (Zeiss, FT 510) and Cy3
(BP365).
U1 targeting constructs
3 modified U1 snRNA anti-hCGβ constructs designated
702P/767A, 702P/767B and 702P/767C were created by
PCR-directed mutagenesis of the 5' sequence between
bases +2 to +11 of a U1 snRNA expression plasmid fol-
lowing previously described methods (9, 10). Bases +2 to
+11 of U1 snRNA normally complement the 5' splice
donor but when mutated, as in these anti-hCGβ  con-
structs, result in a U1 snRNA able to basepair to a target
sequence in the 3' terminal exon of the human hCGβ pre-
mRNA.
Based on numbering from the hCGβ  [Gen-
Bank:NM_033043], plasmid 702P/767A targets nts 848–
857, plasmid 702P/767B targets nts 809–818 and plas-
mid 702P/767C targets nts 779–788. Construct 702P is a
control that expresses wild type U1 snRNA and so should
not target hCGβ. All constructs express GFP off a separate
promoter that serves as a marker for transfected cells. DNA
sequencing was performed to confirm that the mutations
were successfully introduced into the 5' end of the U1
snRNA expression plasmids.
Transfection
HeLa cells were seeded so as to grow to 70–80% conflu-
ence on the day of transfection. Transfection with anti-
hCGβ  constructs utilising lipofectamine™2000 (Invitro-
gene, Carsbad, CA, USA) and FuGENE – HD Transfection
Reagent (Roche Daignostics) was done according to the
manufacturer's protocol. The analyses were performed on
cells harvested 72 h following transfection. Reduction of
hCGβ expression levels by the anti-hCGβ constructs were
calculated after normalization to the control 702P con-
struct.
Apoptosis
The cells transfected with anti-hCGβ  and 702P control
constructs were stained with propidium iodide [0.1 g/ml]
and Hoechst 33342 [0.125 g/ml] (Sigma) 72 hrs after
transfection and chromatin changes typical for apoptosis
was analysed with fluorescence microscope (Nikon
Eclipse TE 200).
Cell cycle analyses
The cells were harvested after treatment fixed in cold 70%
ethanol. Fixed cells were subsequently washed and treated
with 100 µg/ml RNAse A, and stained with 50 µg/ml pro-
pidium iodide. Analyses were performed with BD Facs
Calibur. Three parallel samples were measured and no
less than 10 000 cells were tested in one sample. Cell cycle
distributions were analyses by BD Cell Quest™ Pro
ver.5.2.1 software.
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